BAVA.CO
BAVA.CO
DK0015998017
Bavarian Nordic A/S
Loading chart...

Company Profile

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, England, Finland, Switzerland, Japan, Austria, Italy, Spain, Taiwan, Saudi Arabia, Australia, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Related stocks

ZEAL.CO
ZEAL.CO • Denmark
Zealand Pharma A/S
238 DKK
2.37B USD 1Y -53.5%
ONT.L
ONT.L • United Kingdom
OXFORD NANOPORE TECHNOLOGIES PL
213.4 GBp
2.76B USD 1Y +34.5%
GNS.L
GNS.L • United Kingdom
GENUS PLC ORD 10P
2,280 GBp
1.97B USD 1Y -12.5%
ALK-B.CO
ALK-B.CO • Denmark
ALK-Abelló B A/S
227.4 DKK
7.55B USD 1Y +5.6%
QURE
QURE • Netherlands
uniQure N.V.
22.59 USD
1.57B USD 1Y -62.4%
ASND
ASND • Denmark
Ascendis Pharma A/S
229.23 USD
15.08B USD 1Y +6%
IMCR
IMCR • United Kingdom
Immunocore Holdings plc
29.39 USD
1.51B USD 1Y -14.4%
MEDCL.PA
MEDCL.PA • France
MEDINCELL S.A.
29.06 EUR
1.17B USD 1Y -11.3%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
53.2% p.a.
Max Drawdown (5Y)
-68.5%
Sharpe Ratio (5Y)
-0.15
Beta Factor
0.97
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (53.2% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -72.8% in the extended horizon.
ende